Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Nov. 21, 2017. Steve Niedelman.

Executive Summary

Check out what King & Spalding's Steve Niedelman had to say about device-makers being extra careful about what they tell a US FDA investigator.

"[If] the investigator found something bad, don’t point them to other things that are bad. Instead, take your lumps on the one thing that’s bad and don’t open the kimono for everything else that’s going on. Because if you do, that inspection will just grow. What may have started as what was intended as a week inspection, well, FDA could now be in there for six months. You want to avoid that." – Steve Niedelman, lead quality systems and compliance consultant, King & Spalding

Click here for a free trial of Medtech Insight

Advertisement

Related Content

Compliance Corner: 20 Things You Should Never Say To An FDA Investigator

Topics

Advertisement
UsernamePublicRestriction

Register

MT121787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel